Sangamo Therapeutics (SGMO) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-62.03M
Depreciation and amortization	745K
Amortization of premium / discount on marketable securities
Stock-based compensation	13.13M
Interest receivable	-3K
Accounts receivable	1.04M
Prepaid expenses and other assets	-725K
Accounts payable and accrued liabilities
Accrued compensation and employee benefits	89K
Deferred revenues	-4.09M
Net cash used in operating activities
Purchases of investments
Maturities of investments
Purchases of property and equipment	-509K
Net cash provided by / (used in) investing activities
Proceeds from issuance of common stock	760K
Net cash provided by financing activities
Net decrease in cash and cash equivalents	-41.5M
Cash and cash equivalents, beginning of period	69.48M
Cash and cash equivalents, end of period	27.99M

Entities mentioned with SGMO

View All Entities